Podcasts about Bayer

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über eine kräftige Kurserholung an der Wall Street, Rekordumsätze bei Ark und gute Zahlen bei IBM. Außerdem geht es um Tesla, AirBnB, Netflix, Moderna, Biontech, Datadog, Atlassian, Splunk, Bitcoin, Delivery Hero, HelloFresh, Deutsche Bank, Valneva, Novavax, Curevac, Pfizer, GSK, Bayer, Basisinvestments: iShares Core MSCI World (WKN: A0HGV0), Vanguard ESG Global All Cap (WKN: A2QL8U), SPDR MSCI All Country World IMI (WKN: A1JJTD), Lyxor MSCI ACWI (WKN: LYX00C), iShares Nasdaq US Biotechnology ETF (WKN A2DWAW). "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Holger Zschäpitz, Anja Ettel, Philipp Vetter, Daniel Eckert und Nando Sommerfeldt diskutieren im Wechsel über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 5 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm

Es gibt Führungskräfte, die sich davor scheuen, aufrichtig über ihre Vergangenheit zu berichten. “Wir können nicht sagen, dass du mit 18 Mal in der Logistik bei Bayer gearbeitet hast!” hat eine Recruiterin bei MBB mal gesagt. Zu groß ist die Angst, dass ein falsches Bild entsteht. So ein Quatsch! Das war bei meinem letzten Interview anders … Dr. Magdalena Faulmüller ist Head of Recruiting & Employer Branding bei BDO Germany. Mit etwa 1900 Kolleginnen und Kollegen agiert BDO als eine der führenden Wirtschaftsprüfungen auch mit prüfungsnahen Dienstleistungen und Steuerberatung. Magdalena hat einen bemerkenswerten Lebenslauf, weil sie sich vom Discounter zur Führungskraft mit Doktortitel hochgearbeitet hat. Sie ist ein Vorbild für Integration und Entschlossenheit. Viel Spaß mit der aktuellen Folge! Dr. Magdalena Faulmüller auf LinkedIn: https://www.linkedin.com/in/dr-magdalena-faulm%C3%BCller-81177770/ #Karriere #Recruiting #Consulting Moritz Neuhaus ist Co-Founder und CEO der Insight Consulting GmbH. Gemeinsam mit seinem Team hilft er CEOs, Gründern und Consulting-Partnern dabei, online zu Meinungsführern in ihrer Industrie zu werden. Homepage https://insight.berlin Instagram https://instagram.com/moritz.neuhaus LinkedIn https://www.linkedin.com/in/moritz-neuhaus-ceo-personal-branding Ich freue mich jederzeit über deine Themenwünsche oder Feedback.

Welcome to episode #101! In this episode, I have an amazing conversation with my sister-in Christ, Jen Bayer, Freedom Lifestyle Entrepreneur who has a heart for guiding women through physical and spiritual healing. Do you know anyone who has struggled with negative thoughts/emotions about their bodies? or need healing in mindset about their bodies? Connect with Jen today @jenbayer on IG and FB or www.exaltedhealth.com. Do you want to be a guest on the show or connect with me? Visit www.Bewindi.com or send me a message on IG @empowered2serve. To purchase book, Empowerment for you: Encouragement for your Emotional and Spiritual Wellness, visit https://www.amazon.com/dp/B09JRQC2M4 and to purchase the Empowered to Empower you Reflection Workbook, visit https://www.amazon.com/dp/B09MDGXRVW Better help is a sponsor for this podcast- visit https://betterhelp.com/Bewindi and receive 10% of your first month Love, Bewindi --- Send in a voice message: https://anchor.fm/bewindi-aquilla-bobb/message Support this podcast: https://anchor.fm/bewindi-aquilla-bobb/support

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über das Comeback von Teamviewer, eine grüne Aktie mit Energieverlust und digitale Konkurrenz für Krypto. Außerdem geht es um Goldman Sachs, JPMorgan, Siemens Gamesa, Siemens Energy, Bitcoin, Bayer, Virgin Galactic, Vroom, CureVac, C3.ai, Lemonade, GoHealth, Peloton, QuantumScape, Rivian, Quantumscape, Virgin Galactic, C3.ai, GameStop, Beyond Meat, Palantir, Fiverr, Pinduoduo, MercadoLibre, DoorDash, Etsy, Draftkings, Netflix, Vimeo, DocuSign, Cloudflare, Crowdstrike und Roblox. "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Holger Zschäpitz, Anja Ettel, Philipp Vetter, Daniel Eckert und Nando Sommerfeldt diskutieren im Wechsel über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 5 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm

Quinn and Isaac discuss the hype surrounding NFTs (Non Fungible Tokens), which NFTs they already own, and why they are worth so much money.

Christoph Bayer ist ehemaliger Redakteur von MTB-News.de und dem ENDURO Mag. Mittlerweile arbeitet er für das Kommunikationsbüro Tanne 9. Sie werden ungern Agentur genannt, aber laufen auf dem Blattpapier dann doch unter diesem Namen. Geschichten erzählen ist leicht, aber darin die richtigen Werte und Normen zu transportieren ist schwierig. Warum das für die Bikemarken der Zukunft aber immer wichtiger wird und vieles mehr berichtet uns Christoph Bayer im Interview mit Jasper Jauch.

In der zweiten Woche des neuen Jahres nimmt die Liga langsam Fahrt auf: Die Bayern brillieren gegen überforderte Kölner und besonders Robert Lewandowski sorgt mit seinem Deierpack inklusive BuLi-Treffer Nummer 300 für einen ruhigen Nachmittag. Der BVB hält mit: 5:1 schickt die Borussia die Überflieger aus Freiburg nach Hause. Während die Hertha mit 0:0 in Wolfsburg auf der Stelle tritt, findet das eigentliche Spektakel in Gladbach statt: Yann Sommer hält gegen Bayer zwei Elfmeter allein für einen Sieg der Fohlen reicht es nicht! Die "Doppelspitze" analysiert in dieser Woche einen ereignisreichen Spieltag und blickt voraus auf eine Woche, die jede Menge Pokalfight verspricht inklusive emotional aufgeladenen Tippens aller acht Partien! Einschalten, mitfiebern, genießen, eure Doppelspitze Leon Ginzel (@laeonn) und Henning Schneider (@gewerbeglitzer) Kontakt: Mail an doppelspitze ät posteo punkt de Instagram Facebook Twitter

In der zweiten Woche des neuen Jahres nimmt die Liga langsam Fahrt auf: Die Bayern brillieren gegen überforderte Kölner und besonders Robert Lewandowski sorgt mit seinem Deierpack inklusive BuLi-Treffer Nummer 300 für einen ruhigen Nachmittag. Der BVB hält mit: 5:1 schickt die Borussia die Überflieger aus Freiburg nach Hause. Während die Hertha mit 0:0 in Wolfsburg auf der Stelle tritt, findet das eigentliche Spektakel in Gladbach statt: Yann Sommer hält gegen Bayer zwei Elfmeter allein für einen Sieg der Fohlen reicht es nicht! Die "Doppelspitze" analysiert in dieser Woche einen ereignisreichen Spieltag und blickt voraus auf eine Woche, die jede Menge Pokalfight verspricht inklusive emotional aufgeladenen Tippens aller acht Partien! Einschalten, mitfiebern, genießen, eure Doppelspitze Leon Ginzel (@laeonn) und Henning Schneider (@gewerbeglitzer) Kontakt: Mail an doppelspitze ät posteo punkt de Instagram Facebook Twitter

In der zweiten Woche des neuen Jahres nimmt die Liga langsam Fahrt auf: Die Bayern brillieren gegen überforderte Kölner und besonders Robert Lewandowski sorgt mit seinem Deierpack inklusive BuLi-Treffer Nummer 300 für einen ruhigen Nachmittag. Der BVB hält mit: 5:1 schickt die Borussia die Überflieger aus Freiburg nach Hause. Während die Hertha mit 0:0 in Wolfsburg auf der Stelle tritt, findet das eigentliche Spektakel in Gladbach statt: Yann Sommer hält gegen Bayer zwei Elfmeter allein für einen Sieg der Fohlen reicht es nicht! Die "Doppelspitze" analysiert in dieser Woche einen ereignisreichen Spieltag und blickt voraus auf eine Woche, die jede Menge Pokalfight verspricht inklusive emotional aufgeladenen Tippens aller acht Partien! Einschalten, mitfiebern, genießen, eure Doppelspitze Leon Ginzel (@laeonn) und Henning Schneider (@gewerbeglitzer) Kontakt: Mail an doppelspitze ät posteo punkt de Instagram Facebook Twitter

In der zweiten Woche des neuen Jahres nimmt die Liga langsam Fahrt auf: Die Bayern brillieren gegen überforderte Kölner und besonders Robert Lewandowski sorgt mit seinem Deierpack inklusive BuLi-Treffer Nummer 300 für einen ruhigen Nachmittag. Der BVB hält mit: 5:1 schickt die Borussia die Überflieger aus Freiburg nach Hause. Während die Hertha mit 0:0 in Wolfsburg auf der Stelle tritt, findet das eigentliche Spektakel in Gladbach statt: Yann Sommer hält gegen Bayer zwei Elfmeter allein für einen Sieg der Fohlen reicht es nicht! Die "Doppelspitze" analysiert in dieser Woche einen ereignisreichen Spieltag und blickt voraus auf eine Woche, die jede Menge Pokalfight verspricht inklusive emotional aufgeladenen Tippens aller acht Partien! Einschalten, mitfiebern, genießen, eure Doppelspitze Leon Ginzel (@laeonn) und Henning Schneider (@gewerbeglitzer) Kontakt: Mail an doppelspitze ät posteo punkt de Instagram Facebook Twitter

In der zweiten Woche des neuen Jahres nimmt die Liga langsam Fahrt auf: Die Bayern brillieren gegen überforderte Kölner und besonders Robert Lewandowski sorgt mit seinem Deierpack inklusive BuLi-Treffer Nummer 300 für einen ruhigen Nachmittag. Der BVB hält mit: 5:1 schickt die Borussia die Überflieger aus Freiburg nach Hause. Während die Hertha mit 0:0 in Wolfsburg auf der Stelle tritt, findet das eigentliche Spektakel in Gladbach statt: Yann Sommer hält gegen Bayer zwei Elfmeter – allein für einen Sieg der Fohlen reicht es nicht! Die "Doppelspitze" analysiert in dieser Woche einen ereignisreichen Spieltag und blickt voraus auf eine Woche, die jede Menge Pokalfight verspricht – inklusive emotional aufgeladenen Tippens aller acht Partien!

GET THE SECOND HOUR PLUS OTHER BONUS CONTENT FOR $7 A MONTH Subscribe on Patreon Subscribe on Substack Subscribe on LiberOhio.com (coming soon)   HOLISTIC WELLNESS FUNDRAISING CAMPAIGN Help Ryan start a Private Membership Association centered around holistic wellness & community building: https://www.gofundme.com/f/sol-source-holistic-wellness-sanctuary    IN THIS EPISODE David Whitehead is the host of the Way of the Truth Warrior podcast, cohost of the Unslaved podcast, and the creator of the Cult of the Medics docuseries.   SECOND-HOUR TOPICS More about etymology and symbols re: medics, magistrates, shields and crosses The alchemical cross, vinegar, Jesus and the Holy Sponge IG Farben, the Bayer Maltese Cross and Bayer's killer hemophiliac product The Saturn death (or anti-life) cult The war on germs The Club of Rome and “The Zero Growth Post Industrial Plan for Industry and Agriculture for the United States of America” Why people can't see evil and the collective shadow war   GUEST LINKS Cult of the Medics DW Truth Warrior Unslaved   LIBER, OHIO LINKS Telegram YouTube Bitchute Rumble Odysee   MUSIC Vestron Vulture - “I Want To Be A Robot” Akes J Beats - “Bear”

Responder com confiança numa entrevista de emprego é primordial! Durante este episódio vamos dar uma olhada nas perguntas mais clássicas de todos os entrevistadores, da mais simples a mais complexa. Não se esqueça de conferir a nossa expansão de vocabulário que vai ter mais material relacionado ao tema, assim como nosso e-book Bosch, Siemens e Bayer: se dando bem em uma entrevista em alemão que preparamos para você e que também aborda o tema. Material:

Die Rückrunde ist noch jung, doch von Entspannung keine Spur. Sowohl in dem Kampf um europäische Plätze als beim versuch die Klasse zu halten sind zahlreiche Teams dicht beieinander und jedes Spiel hat das Potential, große tabellarische Auswirkungen nach sich zu ziehen. Das gilt für die Freiburger, die gegen Borussia Dortmund ran müssen genauso wie für Arminia Bielefeld im Duell mit Greuther Fürth. Das Duell zwischen Gladbach und Leverkusen verspricht zudem einiges an Spektakel und lässt die Frage offen, ob Bayer 04 wieder einmal eine Führung verspielen könnte. Auf quasi allen Plätzen der Republik steht damit so einiges auf dem Spiel und da ist es ja gut, dass wir uns im BuLiSpecial um jedes Duell kümmern. Wie immer schaut Moderator Julius Eid gemeinsam mit zahlreichen ExpertInnen auf alle anstehenden Partien des kommenden Bundesligaspieltags. Viel Spaß!

Die Rückrunde ist noch jung, doch von Entspannung keine Spur. Sowohl in dem Kampf um europäische Plätze als beim versuch die Klasse zu halten sind zahlreiche Teams dicht beieinander und jedes Spiel hat das Potential, große tabellarische Auswirkungen nach sich zu ziehen. Das gilt für die Freiburger, die gegen Borussia Dortmund ran müssen genauso wie für Arminia Bielefeld im Duell mit Greuther Fürth. Das Duell zwischen Gladbach und Leverkusen verspricht zudem einiges an Spektakel und lässt die Frage offen, ob Bayer 04 wieder einmal eine Führung verspielen könnte. Auf quasi allen Plätzen der Republik steht damit so einiges auf dem Spiel und da ist es ja gut, dass wir uns im BuLiSpecial um jedes Duell kümmern. Wie immer schaut Moderator Julius Eid gemeinsam mit zahlreichen ExpertInnen auf alle anstehenden Partien des kommenden Bundesligaspieltags. Viel Spaß!

Die Rückrunde ist noch jung, doch von Entspannung keine Spur. Sowohl in dem Kampf um europäische Plätze als beim versuch die Klasse zu halten sind zahlreiche Teams dicht beieinander und jedes Spiel hat das Potential, große tabellarische Auswirkungen nach sich zu ziehen. Das gilt für die Freiburger, die gegen Borussia Dortmund ran müssen genauso wie für Arminia Bielefeld im Duell mit Greuther Fürth. Das Duell zwischen Gladbach und Leverkusen verspricht zudem einiges an Spektakel und lässt die Frage offen, ob Bayer 04 wieder einmal eine Führung verspielen könnte. Auf quasi allen Plätzen der Republik steht damit so einiges auf dem Spiel und da ist es ja gut, dass wir uns im BuLiSpecial um jedes Duell kümmern. Wie immer schaut Moderator Julius Eid gemeinsam mit zahlreichen ExpertInnen auf alle anstehenden Partien des kommenden Bundesligaspieltags. Viel Spaß!

Die Rückrunde ist noch jung, doch von Entspannung keine Spur. Sowohl in dem Kampf um europäische Plätze als beim versuch die Klasse zu halten sind zahlreiche Teams dicht beieinander und jedes Spiel hat das Potential, große tabellarische Auswirkungen nach sich zu ziehen. Das gilt für die Freiburger, die gegen Borussia Dortmund ran müssen genauso wie für Arminia Bielefeld im Duell mit Greuther Fürth. Das Duell zwischen Gladbach und Leverkusen verspricht zudem einiges an Spektakel und lässt die Frage offen, ob Bayer 04 wieder einmal eine Führung verspielen könnte. Auf quasi allen Plätzen der Republik steht damit so einiges auf dem Spiel und da ist es ja gut, dass wir uns im BuLiSpecial um jedes Duell kümmern. Wie immer schaut Moderator Julius Eid gemeinsam mit zahlreichen ExpertInnen auf alle anstehenden Partien des kommenden Bundesligaspieltags. Viel Spaß!

Die Rückrunde ist noch jung, doch von Entspannung keine Spur. Sowohl in dem Kampf um europäische Plätze als beim versuch die Klasse zu halten sind zahlreiche Teams dicht beieinander und jedes Spiel hat das Potential, große tabellarische Auswirkungen nach sich zu ziehen. Das gilt für die Freiburger, die gegen Borussia Dortmund ran müssen genauso wie für Arminia Bielefeld im Duell mit Greuther Fürth. Das Duell zwischen Gladbach und Leverkusen verspricht zudem einiges an Spektakel und lässt die Frage offen, ob Bayer 04 wieder einmal eine Führung verspielen könnte. Auf quasi allen Plätzen der Republik steht damit so einiges auf dem Spiel und da ist es ja gut, dass wir uns im BuLiSpecial um jedes Duell kümmern. Wie immer schaut Moderator Julius Eid gemeinsam mit zahlreichen ExpertInnen auf alle anstehenden Partien des kommenden Bundesligaspieltags. Viel Spaß!

Die Rückrunde ist noch jung, doch von Entspannung keine Spur. Sowohl in dem Kampf um europäische Plätze als beim versuch die Klasse zu halten sind zahlreiche Teams dicht beieinander und jedes Spiel hat das Potential, große tabellarische Auswirkungen nach sich zu ziehen. Das gilt für die Freiburger, die gegen Borussia Dortmund ran müssen genauso wie für Arminia Bielefeld im Duell mit Greuther Fürth. Das Duell zwischen Gladbach und Leverkusen verspricht zudem einiges an Spektakel und lässt die Frage offen, ob Bayer 04 wieder einmal eine Führung verspielen könnte. Auf quasi allen Plätzen der Republik steht damit so einiges auf dem Spiel und da ist es ja gut, dass wir uns im BuLiSpecial um jedes Duell kümmern. Wie immer schaut Moderator Julius Eid gemeinsam mit zahlreichen ExpertInnen auf alle anstehenden Partien des kommenden Bundesligaspieltags. Viel Spaß!

In der 19. Ausgabe des „UNIBET FohlenPodcast – Warm-up“ blickt Florian Neuhaus im Gespräch mit Torsten „Knippi“ Knippertz zurück auf den Rückrundenauftakt beim FC Bayern München sowie voraus auf das anstehende Heimspiel am Samstag (18:30 Uhr) gegen Bayer Leverkusen. Vor dem ersten Heimspiel des neuen Jahres am Samstagabend (18:30 Uhr) gegen Bayer 04 Leverkusen haben sich Florian Neuhaus und Torsten „Knippi“ Knippertz für die Aufzeichnung der 19. Ausgabe des „UNIBET FohlenPodcast – Warm-up“ im BORUSSIA-PARK getroffen. In dem rund 15-minütigen Gespräch und in Abwesenheit von Christoph Kramer blicken die beiden zunächst zurück auf den Rückrundenstart der Fohlen beim FC Bayern München (2:1). In diesem Zusammenhang beschreibt Flo auch die Entstehung seines Treffers zum zwischenzeitlichen 1:1. Darüber hinaus sprechen Knippi und Flo über Neuzugang Marvin Friedrich und die Winter-Transferperiode im Allgemeinen. Flo verrät in dieser Ausgabe des Warm-up zudem, wie Videoanalysen bei Borussia ablaufen und wieso viele Fußballer zu einem und demselben Friseur gehen. Wieso Christoph Kramer bei der Podacst-Aufzeichnung fehlte und wie Neuhaus den anstehenden Bundesliga-Spieltag tippt – das alles und noch viel mehr erfahrt ihr in der 19. Ausgabe des „UNIBET FohlenPodcast – Warm-up“. Hört rein!

Dieser Dienstag ist ein geldpolitischer Großkampftag, zumindest in den USA. Mehrere Fed Gouverneure werden sich zur Geldpolitik äußern und der Chef selber, Jerome Powell, spricht vor dem Bankenausschuss des Senats. Was höhere Zinsen und weniger Liquidität für die Anlagestrategie im neuen Jahr bedeuten, wie sich die Wirtschaft entwickeln wird und welche Branchen interessant sind und ganz konkret welche Aktien oder Hebelprodukte Sie am besten kaufen oder verkaufen, erfahren Sie exklusiv in dieser Clubausgabe 02/22. ( https://go.brn-ag.de/160 ) Behandelte Aktien u.a.: BASF, Bayer, VW, Alibaba, Baidu, Telekom, Siemens Energy, Fresenius, Heidelcement. Werden Sie Clubmitglied: https://www.heiko-thieme.club/anmeldung-monatsabo/

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Daniel Eckert und Philipp Vetter über die Gewinner und Verlierer der Gesundheitsbranche und einen Krypto-Multi-Milliardär. Außerdem geht es um Fresenius, Fresenius Medical Care, Bayer, Brenntag, HelloFresh, Moderna, ASML, Binance, Coinbase, Bitcoin, Ether, Munich Re, den Xtrackers MSCI World Value (WKN: A1103E) und iShares Edge MSCI Europe Value Factor (WKN: A12DPP). "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Holger Zschäpitz, Anja Ettel, Philipp Vetter, Daniel Eckert und Nando Sommerfeldt diskutieren im Wechsel über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 5 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm

Der DAX kann die Gewinne aus der Eröffnung nicht halten und fällt aktuell unter 15.900 Punkte zurück. Auch dies muss kein Trend sein, sondern ist der Vola zum Wochenstart geschuldet, wie unser Händler Daniel hier kommentiert.

Scott and Gage discuss seeing Jesus in the Book of James.ESV Gospel Transformation Study Bible: Christ in All of Scripture, Grace for All of Life: ESV Bibles, Zahl, Paul F. M., Morales, Michael, Long, V. Philips, Thielman, Frank, Bayer, Hans F., Smith, Ian K.: 9781433563591: Amazon.com: BooksThe Son of David (A 10-week Bible Study): Seeing Jesus in the Historical Books (Volume 3): Guthrie, Nancy: 9781433536564: Amazon.com: BooksLogos pre-rollSupport the show (https://www.patreon.com/join/3789852?)

Eugene has spent more than two decades in the healthcare industry taking on different shoes by both driving digital health in pharma, consulting and being an entrepreneur. Among the many things he has been involved in, he used to be the global head of Bayer's digital health partnership and investment arm G4A.  Being a US citizen he had the opportunity to live in multiple countries, which allowed him to see similarities and differences in the developments of the digital health space from a geographical point of view. Nowadays together with his wife he is building up a digital health coaching start-up, which we dove deeper into breaking down the space of telehealth and health coaching.     

Volksmusikreferent Elmar Walter stellt "Bayerischer Dreiklang. Das Liederbuch" vor. Von den Seminaren "Bayerischer Dreiklang" der vergangenen 50 Jahre gingen viele Impulse für die Volksmusikpflege in Bayern aus. Außerdem geht's mit Daniela Sandner vom Bayerischen Landesverein für Heimatpflege um Perchten und Silvesterbräuche.

CHS and Bayer have teamed up to offer a flexible, easy-to-navigate carbon program that rewards farmers for adopting climate-smart practices. Here's how it works. 

CHS and Bayer have teamed up to offer a flexible, easy-to-navigate carbon program that rewards farmers for adopting climate-smart practices. Here's how it works. 

— The factors governing success in personal relationships are complex. It's not simply a matter of whether the other parties in the relationship are “right” for you. It's recognizing the multitude of factors - ranging from the personality types of those with whom you're in relationship to their embedded notions of what's most important in those relationships: affection? — emotional support? shared vales? security? etc.). Becoming aware of these factors, and making adjustments that better align you with your relationship partners (whether in work or in personal life), Is key to more success in navigating them and having them serve as motivators rather than as demotivators. Valeria Teles interviews Jim Weinstein— A Life And Career Counselor, Marriage And Family Therapist, And Speaker Brought up in the New York suburbs (Eastchester), Jim Weinstein attended Wesleyan University in Middletown Connecticut where he majored in Political Science. Graduating magna cum laude Phi Beta Kappa Jim was accepted to Harvard Business School where he concentrated in marketing. He graduated with distinction and thereafter began working in New York for one of America's largest ad agencies, Benton and Bowles, as an account executive. Jim rose quickly in the organization, being named Vice President four years later. In the subsequent 15 years he worked at several other major agencies, including Wells Rich Greene as Executive Vice-President and Chiat/Day as Director of Account Management. Among the clients he serviced were Procter and Gamble, Sony, Coca-Cola, Bayer, Mitsubishi, Fisher-Price, and Energizer (the bunny was developed under my tenure as the lead account manager). In his 40s, Jim embarked on a process of inner work and exploration that led him to move from New York to Los Angeles and to ultimately discover the path of his current career. It started with Jim running a community-based clinical trials organization, Search Alliance, and then co-founding the internet's first psychotherapist search site, 4Therapy.com. He enrolled in Antioch University's clinical psychology program, earning a Master's degree and accumulating 3000 hours of internship training, after which he opened a successful private practice in Beverly Hills. Missing the seasons and the intellectual environment of the East, Jim moved to DC in 2005 making a professional pivot to emphasize career guidance. In the time he had been there he has been fortunate enough to build a thriving practice working with a very diverse, motivated, and intelligent group of clients. Jim is proud to have helped many hundreds of clients to dramatically improve their career and life satisfaction. To learn more about Jim Weinstein and his work, please visit: dclifecounseling.com   — This podcast is a quest for well-being, a quest for a meaningful life through the exploration of fundamental truths, enlightening ideas, insights on physical, mental, and spiritual health. The inspiration is Love. The aspiration is to awaken new ways of thinking that can lead us to a new way of being, being well. 

Vamos falar nesse Called to Coach sobre o Talento Ativação com o convidado Pedro Penido. Pedro é casado com a Vivian desde 2013, pai do Benjamin e da Celeste. Publicitário por formação, Pedro tem especialização em Liderança, Cultura e Teologia pela Hillsong College (Austrália) e certificação em Accelerated Strengths Coaching pela Gallup. Tem experiência atuando em diversas áreas como Compras e Customer Service na IBM, Publicidade e Esportes pela Soccer de Brazil Academy, na Austrália. Desde 2017 empreende na área de Soluções para Pessoas com sua empresa People Business, oferecendo acompanhamentos e treinamentos para os temas de Cultura Organizacional, Liderança e Soft Skills, Pontos Fortes, e Comunicação. Atua também como professor na Escola Conquer, uma das maiores referências no que diz respeito à educação da nova economia, no Brasil. Através dessa e por sua organização, já treinou mais de 5500 pessoas em empresas como ABInBev, Roche, Nubank, Levi's, Ifood, sem contar o curso on-line sobre Inteligência Emocional, no qual foi professor em 3 das 7 aulas para mais de 700 mil alunos inscritos. TOP 05 Pedro Penido: Empatia, Conexão, Crença, Ativação, Desenvolvimento English: He has been married to Vivian since 2013, and has two children: Benjamin and Celeste. An advertiser by training, Pedro holds a specialization in Leadership, Culture and Theology from Hillsong College (Australia) and certification in Accelerated Strengths Coaching from Gallup. He has experience working in several areas such as Purchasing and Customer Service at IBM, Advertising and Sports at Soccer de Brazil Academy, in Australia. Since 2017 he has been working in the People Solutions area with his company People Business, offering follow-up and training on the themes of Organizational Culture, Leadership and Soft Skills, Strengths, and Communication. He also works as a teacher at Escola Conquer, one of the biggest references in terms of education for the new economy in Brazil. Through Conquer and his organization, he has trained more than 5500 people in companies such as ABInBev, Roche, Nubank, Levi's, Ifood, not counting the Conquer's online course on Emotional Intelligence, in which he taught in 3 of the 7 classes for more than 700 thousand students enrolled. Pedro´s Top 05: Empathy, Connectedness, Belief, Activator, Developer Yuri Trafane formou-se em Gestão de Marketing pela ESPM após ter cursado Química na UNICAMP. Possui dois MBAs, um pela USP e outro pela FGV, seguido de um pós-MBA pela FIA, uma certificação em coaching pela ATD USA e uma especialização em Strength Based Coaching pela Gallup USA. Com sólida formação acadêmica, construiu sua experiência profissional como executivo em empresas renomadas, como Johnson & Johnson, Unilever, Parmalat, Bauducco e Grupo Abril.Atualmente dirige a Ynner Treinamentos, empresa de treinamento e consultoria especializada em Gestão, Estratégia, Vendas e Marketing, onde teve o privilégio de formar executivos de empresas de destaque como Bayer, Nestlé, Bosch, Nívea, Walmart, 3M, Eaton , Emerson, Mercedes-Benz, FMC, Mary Kay, Sanofi, Saint Gobain e várias outras. Ynner é a representante oficial da Gallup no Brasil. Yuri's Top 5 CliftonStrengths: Input (Input), Estudioso (Learner), Ativação (Activator), Significância (Significance), Relacionamento (Relator) Learn more about Gallup's other resources for strengths-based coaching: • Articles & Videos • Webcasts • Guides & Reports • Subscribe to our Newsletter To learn about Gallup's other resources for strengths-based coaching, visit Gallup Access. Called to Coach is a Gallup Webcast (via YouTube) that allows current and prospective coaches to interact with strengths coaches who have found success in strengths-based development.

Vamos falar sobre o Talento Futurista nesse Called to Coach com nosso convidado especial Rafael Peixoto. Rafael, possui Mestrado em Marketing pela Université D'Angers na França, MBA em Executive Business Management, Pós-Graduação em Gestão de Projetos e Graduação em Tecnologia da Informação. Hoje, além de Mentor para executivos, Rafael, também, é Treinador de cursos de Liderança em grandes empresas Multinacionais. Paralelamente, exerce a função de Hipnoterapeuta, em seu Consultório Clínico, em Petrópolis-RJ. Recentemente, foi convidado para estrear como Apresentador no programa - A MENTE QUE APRENDE pela emissora TV PETRÓPOLIS, onde gera conteúdo sobre os assuntos: Desenvolvimento Humano Qualidade de Vida Neurociência e Saúde Mental Empreendedorismo e Marketing Rafa, como costuma ser chamado, é Coach de Pontos Fortes desde 2020, certificado pela Ynner Treinamentos, única parceira oficial da Gallup no Brasil. Nos mais de 26 anos de experiência profissional, Rafael já atuou como Analista de Redes de Computadores, Arquiteto de Infraestrutura de IT, Gestor de Projetos, Gestor de Produtos e Marketing e, hoje, é dono do seu próprio negócio, onde fundou à RP CONSULTORIA E TREINAMENTOS. Apaixonado pelo que faz, dedica sua vida para ajudar pessoas e empresas na busca do seu máximo potencial. Entre as suas principais certificações, então: Master Practitioner em PNL Master Professional Coach Trainer Gallup Global Strengths Coach Mentor de Mentores Master em Hipnoterapia Clínica Avançada Especialista em Neurociência Top 05 Rafael Peixoto: EXCELÊNCIA, FUTURISTA, ESTUDIOSO, FOCO e POSITIVO. English: Rafael has a Master's Degree in Marketing from Université D'Angers in France, MBA in Executive Business Management, a Postgraduate Diploma in Project Management, and a Graduation in Information Technology. Today, in addition to mentoring executives, Rafael is also a Leadership Course Coach in large multinational companies. At the same time, he performs the role of Hypnotherapist, in his Clinical Office, in Petrópolis, state of Rio de Janeiro in Brazil. Recently, he was invited to be a TV SHOW HOST, where he generates content on the subjects: Human development Quality of life Neuroscience and Mental Health Entrepreneurship and Marketing With more than 26 years of professional experience, Rafael has already worked as a Computer Network Analyst, IT Infrastructure Architect, Project Manager, Product and Marketing Manager. Nowadays, he has been working in his own business, where he founded RP CONSULTORIA AND TRAININGS. Passionate about what he does, he dedicates his life to helping people and companies pursue their maximum potential. Rafa, as he is often called, has gotten a Strengths Coach Certification since 2020, by Ynner Treinamentos, the only official Gallup partner in Brazil. Among your main certifications, then: Master Practitioner in NLP - Neuro-Linguistic Programming Master Professional Coach Trainer Gallup Global Strengths Coach Mentor of Mentors Master in Advanced Clinical Hypnotherapy Neuroscience Specialist Rafael´s Top 05: MAXIMIZER, FUTURISTIC, LEARNER, FOCUS and POSITIVE. Yuri Trafane formou-se em Gestão de Marketing pela ESPM após ter cursado Química na UNICAMP. Possui dois MBAs, um pela USP e outro pela FGV, seguido de um pós-MBA pela FIA, uma certificação em coaching pela ATD USA e uma especialização em Strength Based Coaching pela Gallup USA. Com sólida formação acadêmica, construiu sua experiência profissional como executivo em empresas renomadas, como Johnson & Johnson, Unilever, Parmalat, Bauducco e Grupo Abril.Atualmente dirige a Ynner Treinamentos, empresa de treinamento e consultoria especializada em Gestão, Estratégia, Vendas e Marketing, onde teve o privilégio de formar executivos de empresas de destaque como Bayer, Nestlé, Bosch, Nívea, Walmart, 3M, Eaton , Emerson, Mercedes-Benz, FMC, Mary Kay, Sanofi, Saint Gobain e várias outras. Ynner é a representante oficial da Gallup no Brasil. Yuri's Top 5 CliftonStrengths: Input (Input), Estudioso (Learner), Ativação (Activator), Significância (Significance), Relacionamento (Relator) Learn more about Gallup's other resources for strengths-based coaching: • Articles & Videos • Webcasts • Guides & Reports • Subscribe to our Newsletter To learn about Gallup's other resources for strengths-based coaching, visit Gallup Access. Called to Coach is a Gallup Webcast (via YouTube) that allows current and prospective coaches to interact with strengths coaches who have found success in strengths-based development.

Relations between Russia and the USA are deteriorating rapidly today. Moscow demanded immediate talks with the US on security guarantees from NATO. A senior Russian diplomat warned that Russia may soon take military action against NATO if the alliance continues to ignore Russia's warnings about weapons and troops in Ukraine. The TruNews team has more information on this very disturbing development. Rick Wiles, Doc Burkhart. Airdate 12/20/21

Farm Talk Segment 1 - David McGlynn - Bayer

Josef Bayer - Die Puppenfee: Ballabile Slovak Radio Symphony Orchestra Andrew Mogrelia, conductor More info about today's track: Naxos 8.557098 Courtesy of Naxos of America, Inc. Subscribe You can subscribe to this podcast in Apple Podcasts, or by using the Daily Download podcast RSS feed. Purchase this recording Amazon

Andrea Picciotti-Bayer is a legal analyst for EWTN News. Supreme Court's NY Decision Is a Blow for Religious Freedom

This episode of the GCSAA Podcast features a conversation with a true legend of golf course management, Paul R. Latshaw.  A 56-year member of the association and the winner of the 2014 Old Tom Morris Award, Latshaw shares stories and insights from his long career in the business, his stops at some of golf's most revered properties — Augusta, Winged Foot, Congressional — and his role in influencing and mentoring a whole new generation of golf course superintendents. The interview was conducted by Howard Richman, GCM's associate editor.The GCSAA Podcast is presented in partnership with Bayer Environmental Science.

“We all need to work together across the entire value chain, even as consumers, to make a difference to ensure that fruit and vegetable consumption really becomes a part of everyone's diet.” Kelly Bristow (39:39-40:00)   The UN declared 2021 as the International Year of Fruits and Vegetables. With this declaration, the UN gifted Bayer with an invitation to raise awareness to the importance of fruit and vegetable consumption and the role it plays in human nutrition, food security, and health. Bayer wanted to take the year as a lens and bring together the important steps across the value chain all the way from seed to ultimately what ends up on consumer's plates. To help increase awareness, consumption, and even enhance flavor of fruits and vegetables.    Kelly Bristow is the Science and Nutrition Partnerships Manager at Bayer and mom to two young kids. She meets with outside organizations and stakeholders to bring together influential people to think globally about how we can impact fruit and vegetable consumption. Jenny Maloney is the Strategic Account Manager for the Americas for Bayer Vegetable Seeds all while being mom to three young girls. Jenny and Kelly, along with Lori, put together a virtual event called Beyond Farm to Table: A Seed's Journey to Your Plate. Bayer wanted to have a holistic look at the food chain, not only looking at it from a grower or retailer perspective, but also a consumer perspective. Bayer pulled together three leading experts in this space. Lori was there moderating the event. They also had David Bell, CMO at Long Vine Growing Company, Chad Street from the Albertson's Company, and Jana Parker from IRI Fresh. All of these different perspectives made for such a great, well-rounded, interactive event.   For Kelly, it was so great to get three different people in different parts of the value together and seeing their different perspectives. One really does play off the other. It's not often you get to see the whole process in one event. It was interesting to Kelly to hear from Jana about what are in shopper's carts. What produce are shoppers buying and what's accompanying it. It was great to hear that shoppers are buying an increased amount of produce and some ways to help improve that consumption even more.   For Jenny, it was interesting to hear David Bell talk about the journey of a tomato. Starting with seed selection, propagation, transferring to a grow house after eight weeks, How they're picked by hand then sorted for quality, and then sold to consumers. The other thing that stuck out was Long Vine Growing Company's Sustainability Program. One of their facilities is located adjacent to a natural gas power plant. They use energy from that plant to power their own greenhouse. Any water that isn't used by the pants is recirculated. Over 90% of their water is recycled. They are ultimately aiming to grow with care.   What Chad really highlighted was the thought and precision that goes into the placement of every piece of produce in the store. There's a whole team behind the scenes that makes it easy to shop for your produce. He was able to shed a lot of light on the behind the scenes work.    “The way we changed our shopping habits, the way we use produce differently, the way we bought produce differently. That all changed in 2020 and we're still sorting out what that's going to mean for the rest of 2021, 2022, and beyond.” Jenny Maloney (33:50-34:07)   Taste, convenience, and price are big motivators for consumers buying produce, but seeing Jana's data to back this up was really eye-opening for Kelly. We see that people are cooking at home more than ever, but they're still looking for the convenience factor. Even though people are spending more time at home, they are still looking for their fruits and vegetables to be easy and quick to buy and make at home. It was interesting to see this data through the lens of the pandemic.   This International Year of Fruits and Vegetables really helped Bayer shine a spotlight on the importance of developmental goals and looking at giving greater visibility to small scale growers. They brought more awareness to food security, nutrition, and even looked at scalable production and consumption. Everyone across the entire value chain needs to work together, even as individual consumers, to make a difference and ensure that fruit and vegetable consumption really becomes a part of everyone's diet, promote healthy habits, and fight against hunger and malnutrition.   You can find the entire event on Seminis YouTube Channel at: https://www.youtube.com/watch?v=VTYjV21I2Io  How to get involved: Join The Produce Moms Group on Facebook and continue the discussion every week!  Reach out to us - we'd love to hear more about where you are in life and business! Find out more here.    If you liked this episode, be sure to subscribe and leave a quick review on iTunes. It would mean the world to hear your feedback and we'd love for you to help us spread the word!

Host Tom Foley invites back Juergen Bayer, Senior Security Adviser for HP to discuss the unique challenges of cybersecurity in healthcare. Also a review of IBM's 2021 Cost of Data Breach Report. And they explore options to protect the enterprise when implementing remote patient monitoring. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

CoQ10 may help blood sugar management in people with MetS Kashan University of Medical Sciences (Iran), December 5, 2021 Daily supplements of coenzyme Q10 may produce beneficial effects on insulin and blood sugar management in people with metabolic syndrome, says a new study. Writing in the PubMed-listed European Journal of Nutrition , researchers from Kashan University of Medical Sciences in Iran report that CoQ10 supplementation was also associated with significant improvements in serum insulin levels, insulin resistance (measured using the homeostatic model assessment: HOMA-IR), and beta-cell function (homeostatic model assessment-beta cell function: HOMA-B). Results showed that participants in the CoQ10 group experienced significant improvements in insulin levels, HOMA-IR, and HOMA-B, while there was also a trend to improved levels of glutathione and reduced levels of malondialdehyde, a reactive carbonyl compound that is a marker of oxidative stress. (NEXT) Eucalyptus compound effective at treating lung damage  University of Melbourne & Monash University (Australia), December 4, 2021 University of Melbourne-led research has shown the flavonoid pinocembrin, derived from Australian eucalyptus trees, has strong anti-inflammatory properties and could be safe and effective at treating lung fibrosis in sheep, a large animal model for human lung disease. Pinocembrin, a flavonoid found in several different type of trees including pine trees and eucalyptus, has been reported to have antioxidant, anti-inflammatory, anti-microbial and anti-cancer properties. "We found that pinocembrin improved lung function, attenuated lung inflammation, and decreased overall pathology scores compared to damaged lungs that were untreated," Dr. Derseh said. "We saw striking anti-inflammatory effects and modest anti-fibrotic remodeling after four weeks of administering pinocembrin." "In lung fluid samples, inflammatory cells called neutrophils dropped from 7.4 percent of total cells to 3.7 percent in the pinocembrin-treated bleomycin-injured lung segments." (NEXT) Study links high cholesterol, cardiovascular disease to plastics University of California at Riverside, December 2, 2021 Plastics, part of modern life, are useful but can pose a significant challenge to the environment and may also constitute a health concern. Indeed, exposure to plastic-associated chemicals, such as base chemical bisphenol A and phthalate plasticizers, can increase the risk of human cardiovascular disease. What underlying mechanisms cause this, however, remain elusive. A team led by Changcheng Zhou, a biomedical scientist at the University of California, Riverside, now raises the hopes of solving the mystery. In a mouse study, the researchers found a phthalate—a chemical used to make plastics more durable—led to increased plasma cholesterol levels. (NEXT) Environmentally sustainable diet linked to health benefits Lund University (Sweden), December 9, 2021 A large population study from Lund University in Sweden has shown that more sustainable dietary habits are linked to health benefits, such as a reduced risk of premature death from cardiovascular disease and cancer. The study is published in The American Journal of Clinical Nutrition. "Our results indicate that dietary guidelines that are beneficial for both planetary health and personal health do exist," says Anna Stubbendorff, doctoral student at Lund University and first author of the study. The EAT-Lancet Commission report describes how the world must transform its food production and consumption if the Earth's already fragile environment and scarce resources are to suffice for 10 billion people in 2050. The report covered six different areas: climate impact, water use, biodiversity, phosphorus and nitrogen use and acidification. (NEXT) Move Over, Wheat! Rye Bread Is Better for Weight Loss Chalmers University (Sweden), December 2, 2021 New research from Chalmers University in Sweden found that dieters who consumed whole-grain rye lost more weight than those who went for refined wheat. In the 12-week-long study, 242 overweight or obese participants were randomly selected to eat either high fiber rye products or refined wheat products in addition to a hypocaloric diet. Those in the rye group lost an average of 6.4 lbs. and more body fat compared to those in the wheat group, who only lost 4 lbs. "Why rye?" On average, a slice of rye bread is relatively low in calories (around 83 calories) and packed with beneficial nutrients like, folate, iron, copper, niacin and vitamin B6. (NEXT) Vitamins C and E associated with decreased inflammation in diabetics Ahvaz Jundishapur University of Medical Sciences (Iran), December 30 2015. The Avicenna Journal of Phytomedicine published the finding of a trial conducted by Iranian researchers of anti-inflammatory effects of vitamin C and vitamin E in male diabetics. It is possible to control insulin resistance and diabetes by modulating inflammatory cytokines and adipokines using chemical drugs or supplementary micronutrients. (NEXT) What's really wrong with the mainstream media Robert Reich,   The Guardian, December 9, 2021 I'm often asked how I keep up with the news. Obviously, I avoid the unhinged rightwing outlets pushing misinformation, disinformation and poisonous lies. But I've also grown wary of the mainstream media – not because it peddles “fake news” but because of three more subtle biases. First, it often favors the status quo. Mainstream journalists wanting to appear serious about public policy rip into progressives for the costs of their proposals, but never ask self-styled “moderates” how they plan to cope with the costs of doing nothing or doing too little about the same problems. A Green New Deal might be expensive but doing nothing about the climate crisis will almost certainly cost far more. Medicare for All will cost a lot, but the price of doing nothing about America's cruel and dysfunctional healthcare system will soon be in the stratosphere. (NEXT) A massive 8-year effort finds that much cancer research can't be replicated SCIENCE NEWS, DECEMBER 7, 2021  After eight years, a project that tried to reproduce the results of key cancer biology studies has finally concluded. And its findings suggest that like research in the social sciences, cancer research has a replication problem. Researchers with the Reproducibility Project: Cancer Biology aimed to replicate 193 experiments from 53 top cancer papers published from 2010 to 2012. But only a quarter of those experiments were able to be reproduced, the team reports in two papers published December 7 in eLife. The researchers couldn't complete the majority of experiments because the team couldn't gather enough information from the original papers or their authors about methods used, or obtain the necessary materials needed to attempt replication. What's more, of the 50 experiments from 23 papers that were reproduced, effect sizes were, on average, 85 percent lower than those reported in the original experiments. Effect sizes indicate how big the effect found in a study is. For example, two studies might find that a certain chemical kills cancer cells, but the chemical kills 30 percent of cells in one experiment and 80 percent of cells in a different experiment. The first experiment has less than half the effect size seen in the second one. (NEXT) Bayer executive: mRNA shots are ‘gene therapy' marketed as ‘vaccines' to gain public trust ‘We probably would have had a 95% refusal rate' for these shots two years ago, but the pandemic and marketing of the injections as ‘vaccines' has made them popular with the public, said Stefan Oelrich. LIFESITE, Wed Nov 10, 2021 The president of Bayer's Pharmaceuticals Division told international “experts” during a globalist health conference that the mRNA COVID-19 shots are indeed “cell and gene therapy” marketed as “vaccines” to be palatable to the public. Stefan Oelrich, president of Bayer's Pharmaceuticals Division, made these comments at this year's World Health Summit, which took place in Berlin from October 24-26 and hosted 6,000 people from 120 countries. Oelrich told his fellow international “experts” from academia, politics, and the private sector that the novel mRNA COVID “vaccines” are actually “cell and gene therapy” that would have otherwise been rejected by the public if not for a “pandemic” and favorable marketing. (NEXT) VAERS Data Indicates the Covid Vaccines Have Killed At Least 140,000 Americans Vasko Kohlmayer.  American Thinker, December 9, 2021 To get an idea of just how dangerous the current Covid vaccines are, we only need to look at the numbers in the government-authorized VAERS database. If we, then, adjust our VEARS number for this variable, we will obtain the result of 140,616 (3,906 x 36). This would represent the number of Americans killed by the Covid vaccines in a period of fewer than 12 months starting in mid-December 2020 through November 26, 2021. Please keep in mind that the above is a very conservative estimate, which we have arrived at by assuming a 20 percent causality link in reported death entries in the VAERS database and the underreporting factor of 36. This, however, is likely a gross understatement of the actual situation. Using less conservative assumptions, many researchers have come up with a higher death toll. Steve Kirsch, Jessica Rose, and Mathew Crawford, for example, estimated in their paper that the vaccines have likely claimed 150,000 lives as of August 28, 2021. If we use the underreporting factor of 100 (one hundred) advocated by David A. Kessler, Ronald Kostoff, and the Department of Health and Human Services we would arrive at the figure of 390,600 deaths attributable to the vaccines. (NEXT) Vaccine Acquired Immune Deficiency Syndrome (VAIDS): 'We should anticipate seeing this immune erosion more widely' FRONTLINE NEWS, Dec 05, 2021 'If immune erosion occurs after two doses and just a few months, how can we exclude the possibility that effects of an untested "booster" will not erode more rapidly and to a greater extent?' A Lancet study comparing vaccinated and unvaccinated people in Sweden was conducted among 1.6 million individuals over nine months. It showed that protection against symptomatic COVID-19 declined with time, such that by six months, some of the more vulnerable vaccinated groups were at greater risk than their unvaccinated peers. Doctors are calling this phenomena in the repeatedly vaccinated “immune erosion” or “acquired immune deficiency”, accounting for elevated incidence of myocarditis and other post-vaccine illnesses that either affect them more rapidly, resulting in death, or more slowly, resulting in chronic illness. First, these vaccines “mis-train” the immune system to recognize only a small part of the virus (the spike protein). Variants that differ, even slightly, in this protein are able to escape the narrow spectrum of antibodies created by the vaccines. Second, the vaccines create “vaccine addicts,” meaning persons become dependent upon regular booster shots, because they have been “vaccinated” only against a tiny portion of a mutating virus. Australian Health Minister Dr. Kerry Chant has stated that COVID will be with us forever and people will “have to get used to” taking endless vaccines. “This will be a regular cycle of vaccination and revaccination.” Third, the vaccines do not prevent infection in the nose and upper airways, and vaccinated individuals have been shown to have much higher viral loads in these regions. This leads to the vaccinated becoming “super-spreaders” as they carry extremely high viral loads. In addition, the vaccinated become more clinically ill than the unvaccinated. Scotland reported that the infection fatality rate in the vaccinated is 3.3 times the unvaccinated, and the risk of death if hospitalized is 2.15 times the unvaccinated. Indefinite uncontrolled autoimmune response to the coronavirus spike protein may produce a wave of antibodies called anti-idiotype antibodies or Ab2s that continue to damage human bodies long after clearing either Sars-Cov-2 itself or those spike proteins that the shots cause the body's cells to produce, explained former New York Times reporter Alex Berenson. Spike protein antibodies may themselves produce a second wave of antibodies, called anti-idiotype antibodies or Ab2s. Those Ab2s may modulate the immune system's initial response by binding with and destroying the first wave of antibodies. “While some are concerned that blood IgG antibodies fall with time, I am not convinced that this is a relevant measure,” Yeadon continued. "Respiratory virus infection begins in the lungs and nasopharynx. Neither are protected by blood antibodies, which are molecules too large to diffuse into airways tissue. What protects against infection and initial viral replication is secretory IgA antibodies and T-cells in airways, neither of which have been studied in any efficacy trial. "The empirical data are very worrying. In most countries now, high fractions of the population have been vaccinated. If the Swedish study is a guide, we should anticipate seeing this immune erosion more widely. The most concerning aspect of that study is that those most in need of protection are those in whom immune erosion is most marked: the elderly, males, and those with comorbidities. "Some have used the results of this study to support the widespread use of so-called ‘booster' shots. It has to be said: No one has any safety data about such a plan. If immune erosion occurs after two doses and just a few months, how can we exclude the possibility that effects of an untested ‘booster' will not erode more rapidly and to a greater extent? And what then would be the response? A fourth injection. Madness. Yeadon concluded: "Europe is all but gone. The lights are going out. Austria and Germany now subject their unvaccinated to house arrest. In Greece, the unvaccinated are subject to escalating fines, non-payment of which is converted into prison time. In Lithuania, the unvaccinated are excluded from society. The booster campaigns are running full-pelt everywhere. “Someone, somewhere knows what's going to happen. Will immunity-erosion worsen more speedily and to a greater extent after this untested ‘booster'? The U.K. government has already said that the fourth injection is to take place a mere three months after the third. It's utter madness. Yet such is the hermetic control of media that nothing much emerges into the public consciousness.”

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Daniel Eckert und Anja Ettel über den Absturz bei Peloton, einen Triumph für Bayer und einen Inflationsschutz der ganz anderen Art. Außerdem geht es um Crowdstrike, Atlassian, Zoom Video, DocuSign, AMD, Splunk, Okta, Oracle, Broadcom, Tesla, VW, Deutsche Bank, Siemens Healthineers, Lanxess, Covestro, Traton, Vitesco, JP Morgan, Morgan Stanley, ING, BNP Paribas und Lyxor Euro Stoxx Banks (WKN: LYX0Z5). "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Holger Zschäpitz, Anja Ettel, Philipp Vetter, Daniel Eckert und Nando Sommerfeldt diskutieren im Wechsel über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 6 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören.

Guest host, Dr. Neeraj Agarwal, ASCO Daily News editor-in-chief and director of the Genitourinary Cancers Program at the University of Utah's Huntsman Cancer Institute, discusses the practice-changing KEYNOTE-564 and SWOG 1500 trials with Drs. Toni Choueiri and Sumanta "Monty" Pal. Dr. Choueiri is director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Dr. Pal is co-director of City of Hope's Kidney Cancer Program and associate editor of Cancer.Net. (This episode was recorded on 11/18/2021) Transcript Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News podcast. I am Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program, and the professor of Medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome two internationally recognized leaders in the field, Dr. Toni Choueiri and Dr. Sumanta (Monty) Pal, for a discussion about two practice-changing studies in kidney cancer published this year-- KEYNOTE-564 and SWOG 1500. As a quick introduction, Dr. Choueiri is the director of Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute. He's also the Jerome and Nancy Kohlberg Chair, and professor of medicine at the Harvard Medical School. Dr. Sumanta "Monty" Pal is a professor in oncology, and co-director of City of Hope's Kidney Cancer Program, and he is an associate editor of cancer.net of ASCO. Our full disclosures are available in the show notes. And disclosures relating to all episodes of podcasts can be found on our transcripts at ASCO.org/podcast. Toni and Monty, what a day it has been for our patients with kidney cancer. I woke up with the news of the U.S. Food and Drug Administration (FDA) approval of the first ever adjuvant immunotherapy for patients with renal cell carcinoma. It is so great to have you both on the podcast today.   Dr. Monty Pal: Glad to be here. Thanks, Neeraj.   Dr. Toni Choueiri: Thank you, Neeraj. So glad to be here.   Dr. Neeraj Agarwal: So, let me start by asking questions to you first, Toni. So, you recently published the primary results of the phase 3 KEYNOTE-564 study, showing the efficacy of adjuvant therapy with pembrolizumab and immune checkpoint inhibitor in patients with renal cell carcinoma. And this study led to the approval of pembrolizumab this morning. So, please tell us more about the study design and why did you do this study.   Dr. Toni Choueiri: Thank you, Neeraj. And thank you, really, ASCO for this wonderful podcast series. And a big hit, I always listen to them when I'm driving or jogging. And really, thanks for this opportunity because kidney cancer adjuvant therapy has been something like a holy grail we're trying to find for a long, long time. The first adjuvant trial, a randomized trial, in renal cell cancer was in 1973 with radiation therapy. And since that time, all the trials except for one have been a complete failure in a way. And the first adjuvant immunotherapy trial was with old immunotherapy cytokine that we don't use much anymore and was in 1992. I was not done with medical school. I was not actually done with high school at that time, let alone medical school. And now that we have, as we all know, a revolution in the oncology field through these immune checkpoint inhibitors that reinvented immunotherapy in cancer, and now that pembrolizumab has shown activity in patients with more advanced disease, we thought about taking this into the adjuvant setting, a setting of patients where they were subjected to surgery. But on the pathology report, we knew that their risk of this cancer coming back, of recurrence, is somewhat intermediate high or high. These are patients that have stage 2 but grade 4, stage 3, D3, D4. These are patients that had node-positive resected. And we took even patients where the kidney is out, but, also, they had a removal of a metastatic site--let's say a lung metastasis--within a year of removing the kidney. And we know these patients we refer to as M1NED are at quite high risk of recurrence. And we randomly assigned 994 patients to receive pembrolizumab for a year versus placebo. And after a median follow-up of only 2 years--so I want to insist here that this is short for any trial in general--we saw a decrease in the risk of recurrence or death. The hazard ratio for disease-free survival was 0.68. So, a 32% decrease in the risk of recurrence or death. We looked at safety, and we already are familiar in the field of GU oncology with pembrolizumab. And we didn't see when we looked at the safety profile any surprises, any enhanced toxicity. Of course, immune-related adverse events are the number one concern with pembrolizumab. There were no deaths on trial related to pembrolizumab. We saw around 7% of patients needing high dose steroid to medicate these immune-related adverse event, and some patients had to come off therapy for that. We also took a look, Neeraj, an early look, at overall survival. We only had 25% of events, 51 deaths. And we did not meet the very rigorous statistical significance that is needed to say that study is positive for overall survival. But the hazard ratio was 0.54, a 46% decrease in the risk of death, which is kind of encouraging. And after a year, the curve starts to separate. Before a year, they're not separating. And that is consistent with prior studies in general.   Dr. Neeraj Agarwal: This is a very interesting point you just raised, that DFS, disease-free survival, is strongly positive. And even overall survival is trending in the right direction, right?   Dr. Toni Choueiri: Correct.   Dr. Neeraj Agarwal: That's great. So obviously, I would like to raise another point here. When we talk about adjuvant study, we usually think about a localized kidney cancer, which is removed by the surgeon, and then [the] patient is coming to see us for treatment in adjuvant setting. But this study, I would like to highlight, as you said, also included patients who had oligometastatic disease, had successful surgical removal of the oligometastatic disease, and they were also eligible for this trial.   Dr. Toni Choueiri: Yes, absolutely. And I think this is somewhat on the recent side in clinical trials in kidney cancer. The reason for that is that, in practice, we see those patients. And we even had two small trials in the TKI era with sorafenib and pazopanib, small studies, were also completely negative. So, we thought here that we should not exclude these patients. They end up being 6%, 7% of all participants, but this remains an area of unmet medical need.   Dr. Neeraj Agarwal: So, how is the hazard ratio in those patients who had metastatic disease removed and then treated with pembrolizumab?   Dr. Toni Choueiri: Yeah, it was very low. It was 0.2, so 0.29. And this was great to see. I don't want to go into really over-interpreting these results. All the hazard ratio--when you look at subgroup analysis or in the forest plot, all the hazard ratio are less than 1. We didn't see something--let's say 1.5--in favor of pembrolizumab. Now you go into a smaller subgroup, then your confidence intervals are very large and hard to interpret, except that to say, look, on average there could be a significant benefit here, but we can't tell.   Dr. Neeraj Agarwal: Sure, absolutely. I agree with you. So, how this is going to affect the current treatment paradigm, which is for patients with newly diagnosed metastatic RCC, where combination of VEGF-TKI plus immunotherapies (IOs) or IO/IO combinations have become standard of care or treatment paradigm?   Dr. Toni Choueiri: I do believe it will be a standard of care currently in the right population. There are a lot of unanswered questions, but that will be answered hopefully with more follow up. We have already, beside these results, reported--so these results were reported in the plenary session at the 2021 ASCO [Annual Meeting]. But later on, another analysis dealing with patient-reported outcome and quality of life was reported at ESMO and also showed no detriment in quality of life--that's the voice of the patient--no detriment with pembrolizumab (pembro). There is a lot still to do and a lot of unanswered questions, such as the non-clear cell histology, those patients who had surgery of their metastatic disease more than a year. But most important, I think, two questions. One, how can you know from the get-go who are the patients that need adjuvant pembrolizumab? We do not have any valid ctDNA. And I know Dr. Pal was involved with a lot of these type of research. We don't have any ctDNA test that is really that faithful and sensitive in the MRD space in renal cell. Many of us are working, so we don't know. We may end up over-treating patients that need surgery only. And actually, we may end up under-treating patients that need, perhaps, pembro, and another drug. And the second thing in those patients--and I hope it does not happen, but unfortunately, it will to some extent--whose tumor progress on adjuvant pembrolizumab, what do you do? What's the treatment paradigm? And actually, there is no data. This is a data-free zone. And I would think somebody whose tumor progressed, tumor continued to grow or grows, while they're actively on pembrolizumab, on IO, is way different than someone whose tumor comes back after 2 or 3 years from stopping the drug. Should we treat them with the same drug? Should we treat them with the TKI plus IO? Luckily, there are trials that are ongoing in patients whose tumor progressed after PD-1/PD-L1 inhibitor to give them a TKI as a control arm, or a TKI plus an immune checkpoint inhibitor. And I know Dr. Pal is very heavily involved with such trials. So, hopefully, we will answer this question, but not anytime soon.   Dr. Neeraj Agarwal: Very interesting, and definitely new results are posing new challenges in how we practice medicine here in the coming future. So, Monty, you are leading a trial with a very similar trial with atezolizumab. And I'm really hoping, we are all really hoping, that we see the other trial being positive, so we have more treatment options for our patients.   Dr. Monty Pal: I couldn't agree with you more. I mean, I definitely think that Toni's study really adds a lot of fuel to the fire suggesting that this strategy of adjuvant immunotherapy may be successful in localized renal cell.   Dr. Neeraj Agarwal: And I'm not going to really delve into the side effects of pembrolizumab and atezolizumab because these drugs are used quite often. They are in widespread use for different types of cancer. But just a quick question, any safety signal, Toni? Did you see any safety signal with pembrolizumab in this patient population?   Dr. Toni Choueiri: Yeah, this is an excellent question. So, nothing that would be different than using pembrolizumab overall knowing in other diseases as a single agent. So, this drug not first in human, as you know, and it's been approved in combination or as a single agent in many diseases. A tumor that the three of us treat is bladder cancer, and we know from another study how to use pembrolizumab. I think that the use of corticosteroid is somewhat of an objective way, at least to me, in looking at immune-related adverse event. And it has been between 5% to 10%, so we're not way off here. But there is no doubt that there are patients that we had no death on trial attributed to drug that may have, with pembrolizumab, some serious toxicities. We had patients that had autoimmune diabetes, hypophysitis, pneumonitis--quite uncommon, but not impossible.   Dr. Neeraj Agarwal: We'll still need to keep an eye for that, basically.   Dr. Toni Choueiri: No doubt.   Dr. Neeraj Agarwal: Yes. So, changing gears, let's talk to you, Monty. You recently presented the primary results of the SWOG 1500 trial in patients with metastatic non-clear cell renal cell carcinoma. Could you please tell us why you did this study and how this study's design was unique compared to similar studies in this setting?   Dr. Monty Pal: Yeah. No, absolutely. Toni did a great job of outlining areas that are sort of free of data in the adjuvant space, particularly with immunotherapy. I think that data-free area for us in kidney cancer for a long time has been non-clear cell histology. We just don't really know how to treat them. And I actually got advice from Toni when I was devising SWOG 1500. We planned it out as a very simple study comparing sunitinib and cabozantinib. And Toni will remember this history well. It sort of went through several iterations. The study blossomed into a six-arm trial. Ultimately, it turned into a four-arm study, looking at sunitinib versus cabozantinib versus two other MET inhibitors--savolitinib and crizotinib. And ultimately, the study was boiled down to essentially what we'd originally proposed. Two of the MET inhibitors--savolitinib and crizotinib--failed to surpass that initial analysis for PFS. So, ultimately, we demonstrated a superiority with cabozantinib over sunitinib for progression-free survival.   Dr. Neeraj Agarwal: So, what is the current treatment paradigm for patients who have newly diagnosed metastatic papillary RCC now?   Dr. Monty Pal: I think for patients who don't have genomic selection, I think that cabozantinib remains the standard. I really want to champion- and maybe Toni can talk a little bit more about this--a study that Toni is leading called the SAMETA trial, which I think has a really innovative design. And it's going to be genomically characterizing patients and randomizing to savolitinib with durvalumab or sunitinib. Tell me, Toni, if I have the design right there.   Dr. Toni Choueiri: Yes. Actually, this is a specific study in a specific population. It's not in papillary RCC as much as in those 30%, 40% of papillary RCC that have MET-driven tumors, so MET alteration, whether through chromosome 7 duplication, through chromosome 7 trisomy, through mutation or amplification. These patients will get either control arm or they will get savolitinib, which is a pure MET inhibitor that is devoid of VEGF-related toxicities, savolitinib plus durvalumab, or durvalumab alone. So, two experimental arms and one control. And the reason for this is we saw activity and quite a good toxicity profile with savolitinib, a pure MET inhibitor, over sunitinib in an earlier trial that was sunitinib against savolitinib in selected patient populations. The study had to close early. So, despite the numerical difference, this was not statistically significant. And then in another study led by Dr. Powles and colleagues, there was also some interesting activity how durvalumab could augment that activity. So, we're launching a phase 3 trial with three arms that you described very well.   Dr. Neeraj Agarwal: That's wonderful. So, what are the next steps, Monty? I mean, this is amazing to see you designing an investigator-initiated trial. This was your concept. You designed it. You built this to be a huge multicenter trial, which was open across the country, funded by the National Cancer Institute. And congratulations for making that happen. It's rare for us to see these trials going from a concept stage to a national trial, and then changing the standard of care. So, what are the next steps now for you and your team in SWOG for papillary RCC or metastatic papillary RCC? How do you build out further with the backbone of cabozantinib?   Dr. Monty Pal: I really appreciate the question, Neeraj. It's so critical to understand that we're just not quite done yet. Toni's study, as I've mentioned, is incredibly innovative. I'm also really thrilled to be working with someone who you've mentored so well, Ben Maughan, at the Huntsman Cancer Institute in Utah. And he's actually designed a brilliant study, which we're going to be leading together, which looks at cabozantinib with or without atezolizumab. Recently, in a study that you and I and Toni were a part of that we just published in JCO, we actually saw quite impressive response rates with the combination of cabozantinib and atezolizumab in patients with papillary RCC, around 47%. Those response rates were actually replicated in a separate study run by Joe Lee at Memorial Sloan Kettering. In the context of papillary disease response rates were again above a threshold of around 40%. So, I think there's something to it. But until we really subject this to randomization, I think we're not going to know whether or not cabo plus IO is standard. So, I encourage everyone to consider Toni's study. I encourage everyone to look out for our trial of cabo plus or minus atezo, which should be rolling out next year.   Dr. Neeraj Agarwal: What is the name of the trial, or the number, for our audience?   Dr. Monty Pal: Yeah, we lucked out with another great number. We got 1500 for the first trial. This is going to be SWOG 2200. So SWOG 2200, and I think it's due to open maybe in the first quarter of 2022.   Dr. Neeraj Agarwal: That's fantastic news. Any new signal? We know cabozantinib is already approved for our patients with metastatic RCC, courtesy METEOR trial led by Dr. Choueiri. Toni, it's amazing to see how many times you have changed standard of care for our patients with metastatic RCC. So, any new safety signal of cabozantinib in this patient population with metastatic papillary RCC?   Dr. Monty Pal: Nothing that appreciated. The toxicity profile was pretty much on par with what you'd anticipate for cabozantinib in the setting. Major side effects were hypertension, hand-foot syndrome, [and] diarrhea. Nothing that really sort of stood out relative to what we would expect in a clear cell population of patients.   Dr. Neeraj Agarwal: That's great. Any final messages for our patients, for our audience, for our listeners?   Dr. Toni Choueiri: Well, let me start, and maybe Monty can add. It's been, and it hopefully will continue to be, this humbling experience, where median survival from metastatic RCC in mid-2000--not long time ago during our training--has been 1 year. And now in metastatic disease, it's 4 to 5 years. And that is only going to get better. And then it's even more humbling to be in a time where you can talk about adjuvant treatment in this disease, renal cell cancer, that continues every year to kill, unfortunately, 14,000 Americans. That's just in the U.S. alone. So, we have to continue in getting more targets, more drugs, more reasonable combination, and the right patient, whether through specific biomarker that are tissue or blood-based or specific liquid biopsies that can tell you who has and who doesn't have cancer at the microscopic levels.   Dr. Neeraj Agarwal: Thank you. How about you, Monty? Any final message for our audience?   Dr. Monty Pal: I couldn't have summarized it better than Toni, just such a wonderful statement around optimism for what we've achieved so far and what's yet to come. And if I could emphasize to anyone in the audience today the need to keep progressing the field further with clinical trials, I think that would be my underlying message.   Dr. Neeraj Agarwal: Thank you again, Toni, Monty, for your valuable insights and thoughts. Thank you for all the inspiration. This is indeed so inspiring to see your work, which is changing the lives of our patients on a daily basis. Our listeners will find links to your studies in the transcript of this episode. I wish you all the best.   Dr. Toni Choueiri: Thank you.   Dr. Neeraj Agarwal: And thank you to our listeners for your time today. If you enjoyed this episode, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you so much.   Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Exelixis, Pfizer, Merck    , Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Foundation Medicine, Gilead Sciences Research Funding (inst.): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, ORIC Pharmaceuticals, crispr therapeutics, and Arvinas   Dr. Sumanta (Monty) Pal: Consulting or Advisory Role: F. Hoffmann LaRoche, F. Hoffman Research Funding (inst.): Eisai, Genentech, Roche, Exelixis, Pfizer Travel, Accommodations, Expenses: Genentech, Seattle Genetics   Dr. Toni Choueiri: Employment: Dana Farber Cancer Hospital Leadership: Dana Farber Cancer Hospital, NCCN, KidneyCan, ASCO, ESMO Stock and Other Ownership Interests: Pionyr, TEMPEST Honoraria: NCCN, UpToDate, Michael J. Hennessy Associates, ASCO, Harborside Press, Analysis Group,                AstraZeneca, Alexion Pharmaceuticals, Sanofi/Aventis, Bayer, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck          , Novartis, Peloton Therapeutics , Pfizer, Corvus Pharmaceuticals, Ipsen,                 Foundation Medicine, Eisai, PlatformQ Health, Clinical Care Options, Navinata Healthcare, Kidney Cancer Journal, Exelixis, Prometheus, Lpath, NEJM, Lancet Oncology, Cerulean Pharma, alligent, EMD Serono, HERON, Lilly, Janssen Oncology, IQvia, Aveo, and NCI. Consulting or Advisory Role: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol-Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Exelixis, Prometheus Laboratories, alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, Sanofi/Aventis, Peloton Therapeutics, UpToDate, NCCN, Michael J. Hennessy Associates, Analysis Group, Kidney Cancer Journal, Clinical Care Options, Paltform Q, Navinata Healthcare, Harborside Press, ASCO, NEJM, Lancet Oncology, EMD Serono, HERON, Lilly, ESMO, NiKang Therapeutics, Kanaph Therapeutics, Infinity Pharmaceuticals, and Aravive Research Funding (inst.): Pfizer, Novartis, Merck, Exelixis               , TRACON Pharma, GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, Peloton Therapeutics, Roche/Genentech, Celldex, Agensys, Eisai, Takeda, Prometheus, Ipsen, Corvus Pharmaceuticals, Cerulean Pharma, Seattle Genetics/Astellas, Bayer, Foundation Medicine, Roche, Calithera Biosciences, Analysis Group, NCI, GATEWAY for Cancer Research, and Congressionally Directed Medical Research Programs (DOD) Patents, Royalties, Other Intellectual Property (inst.): International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy, International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response Patents, Royalties, Other Intellectual Property: ctDNA technologies Travel, Accommodations, Expenses: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol-Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Exelixis, Prometheus, alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, Sanofi/Aventis, UpToDate, Peloton Therapeutics, NCCN, Michael J. Hennessy Associates, Analysis Group, Kidney Cancer Journal, Clinical Care Options, PlatformQ Health, Harborside Press, Navinata Healthcare, NEJM, Lancet Oncology, EMD Serono, HERON, Lilly, and ESMO Other Relationship: Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Award-winning professor and writer Bart Elmore chats with Trey Elling about SEED MONEY: MONSANTO'S PAST AND OUR FOOD FUTURE. Questions include: What does Coca Cola have to do with Monsanto's earliest days? When did Monsanto get into agricultural chemicals and pesticides? Was Monsanto actively covering up the potential harms of the chemicals the produced 50+ years ago? What is the Technology Use Agreement (TUA) Monsanto requires farmers to sign who use their genetically engineered seeds? How big a problem was the radioactive phosphate slag that the EPA discovered at Monsanto's Soda Springs, ID facility in the 1970s? How did Monsanto react to farmers reporting of Roundup-resistant weeds in the early 2000s? How influential is Monsanto within local, state, and federal governments? Why did Bayer buy Monsanto in 2018, considering all of the legal problems piling up for the latter? Have GE crops improved food production, like MOnsanto has promised since the 1990s?

On this week's episode of Inside Outside Innovation, we sit down with Dr. Ben Bensaou, Professor at INSEAD and author of the new book Built to Innovate. We talk about some interesting case studies and essential practices that companies can use to make innovation accessible to everyone in the organization. Let's get started. Inside Outside Innovation is a podcast to help the new innovators navigate what's next. Each week, we'll give you a front row seat into what it takes to learn, grow, and thrive in today's world of accelerating change and uncertainty. Join us as we explore, engage, and experiment with the best and the brightest innovators, entrepreneurs, and pioneering businesses. It's time to get started.Interview Transcript of Dr. Ben Bensaou, Professor at INSEAD and Author of Built to InnovateBrian Ardinger: Welcome to another episode of Inside Outside Innovation. I'm your host Brian Ardinger. And as always, we have another amazing guest. Today, we have Dr. Ben Bensaou. He is the professor and former Dean of Executive Education at INSEAD and author of the new book, Built to Innovate: Essential Practices to Wire Innovation into your Company's DNA. Welcome to the show, Ben.Ben Bensaou: Good morning, Brian. And thank you for having me. Brian Ardinger: I'm excited to have you. And I understand you're in Japan right now, so we're different sides of the world. You've got a new book out called Built to Innovate. But I wanted to step back and talk about how did you get into the field of innovation research.Ben Bensaou: Well, actually, as a matter of fact, I got into the field of innovation starting where I am right now. I did my PhD looking at Japanese firms. And I had lived in Japan before, but my PhD at MIT Sloan was on the way that Japanese firms were actually developing production systems. And a production system was the quality management movement.So, I was in Japan at the time. And then when I went back and joined INSEAD, I continued my interest in Japanese firms, but this time I want to know what they were doing in the field of innovation. And this is how I got involved with companies in Japan and outside of Japan. Mostly its established firms who are trying to become more innovative.Brian Ardinger: One of the things that we think about is corporations, it's hard for them to innovate. Maybe now it's a little bit more thought of is, you know with all the disruption from everything from COVID to new technologies and that. Companies are a little bit more aware of the fact that they need to be innovating and that the world is changing around them. Can you talk a little bit about how your research and your experience in the field of innovation has changed and evolved over the years? Ben Bensaou: Yes. I would say that one thing that I've noticed over the years, I've been doing my teaching innovation and also helping firms is that I noticed that number one, a lot of people, a lot of organizations equate innovation with launching a new blockbuster product or coming up with a life changing new business model.Many also think that you need to have a genius leader or to be a startup by a matter of fact, to be innovative, to be able to innovate. But I found out that it's not true. I found in my research established even centuries old companies are able to innovate. How did they do this? Well, they don't only focus on industry changing effects, but also for small important changes, very often in unexpected places.And for this, what they do is that they rely on continuous and systematic innovation. Innovation of all kinds. And innovation driven by everyone in the organization. And that's what Built to Innovate is about. It's really about how do you embed continuous innovation inside an organization using a systematic approach.Brian Ardinger: I think that's so important because a lot of corporations that I've talked to want innovation to happen somewhere else. Or like they have their teams and they're executing on their business model and they're optimizing that, but they want innovation to happen somewhere else. So, they create an innovation lab or something and they throw the idea over to someone else to execute. But what I've seen, and I think what it's apparent in your book, and the examples you give is that again, to survive in this changing world, we all have to become innovators. And it doesn't mean, like you said, you have to come up with the next electric car, but you have to find problems and take those early ideas and then innovate them and execute on them so that they become value creation, parts of the business.Ben Bensaou: Absolutely. Absolutely. I find so many people expecting that the innovation is going to come from the leaders. Or, you know, like you say, they create a skunkworks, or they create specialist units that are supposed to do all the innovations for the company. And I think many organizations, and I found this very innovative companies in my research, are able to enlist and leverage the capability of everyone in the organization. For this, what they do is that that they create what I call an innovating engine. Which is a protected, fully legitimized and organized space within the company where everyone can innovate. Not just the specialist. You can innovate in everything you do. I mean, you can innovate of course, in your products and services, but you can innovate in your processes as well, or your internal functions. You can innovate in HR and legal. And you can make innovating a regular habit. Not a sporadic kind of burst of creativity when there's a crisis. And that's what I think I've seen some of these innovative companies do is to create this innovating engine. And leveraging everybody's inate capabilities. Brian Ardinger: So, what do you think are some of the common myths or mistakes that companies make when it comes to executing or putting these innovation initiatives into place.Ben Bensaou: I think it's always the same thing is that many of these organizations, like you were talking earlier about startups, don't have the problem of size. When they start, they're all innovating in a sense innovating mode. Everybody is in contact with customers. But as soon as you grow, you start to be dominated by an execution logic. And the execution, what I call the execution takes over. And the execution engine takes over. And the execution changing is very much about control. It's no surprise that many organizations, established organizations, develop hierarchies and vertical silos focused on supplier side view challenges. And innovating in a sense is less about control. Is more about delegating and is more about collaboration. Is more about teamwork. Horizontal structures that are focused on the customer. Like you said earlier, I think this is a very important word. You said innovation is about problem finding. What kind of new problems do we need to find to solve for the customers. And execution is very much about problem solving. It's a very convergent mindset.And I think this is where a lot of companies fail. Is that they don't realize that when you move into innovating and what I'm saying is that when you create an innovating engine, you allow for every employee to be able to spend time doing some innovating activity in the space of the invading engine. And at that time, they need to switch their mind. They need to switch from a supply side view to a customer side view. Brian Ardinger: That's really interesting because too many folks forego or forget about that exploration side of the business. That a lot of companies don't measure or reward for that type of activity as well. What are your thoughts when it comes to why is it so hard for employees to be innovating?Ben Bensaou: As a matter of fact, I would almost say that it's not very difficult for frontline people to be innovating. We can come back later to the importance of middle management, but I think it's said the dominance, I would almost say the tyranny of the execution mindset stops people from genuinely discovering what the customer really needs.So, for me, when people are switching from an execution mode to an innovating mode, they have to embrace a customer perspective. And there, there are three challenges that I like to think about. One is to listen to what I call the voice of the customer. What are the likes, the pain points, the wishes of the customer? And when you are in innovating mode, you have to switch away from the traditional tell mode or even worse, sometimes people are in complete sell mode and try to be in a listening mode very much with empathy for the customer. The second challenge I think, is about listening to what I call the silence of the customer. The silence of the customer is the things they don't tell you. They don't tell you. And they don't tell you about it either because they don't know or because they know, but they don't think it's your problem to solve. So maybe it could be interesting for the audience. I give you an example about how Phillips, I mean the Dutch appliance and consumer electronics company, develop the first kettle with limescale mouth filter. So, there was a colleague who was a consultant in a consulting firm, and he was part of the team was helping Phillips re-energize their market share for kettles in the UK market. The team leader at some point asked some of the team members to spend a few days and actually live in families in the UK. Observing how customers use their kettles.And after a few days, the members noticed that people were facing a problem they never told them about. I mean, when they were trying to pour the boiling water into the cup of tea. I guess, because the water had a lot of calcium, there was this little coat of limescale floating on top of the tea. And it's very interesting because the customer knew about the problem. It was obvious because they were trying to scoop the limescale with their spoon. But they never told the kettle manufacturer. As a matter of fact, they complain about it, but they complained to the water authorities, not to cattle manufacturer. Brian Ardinger: Interesting. Ben Bensaou: So, this is very interesting because it took only a few months for engineers at Phillips to develop this little filter, which you can find in any kettle these days, that blocks or stops the limescale. So, each time you pour the water, it stops the limescale from getting in your tea. This is what I call the silence of the customer. The customer wouldn't tell you about it. So, you need to find this problem in spite of the customer. Not thanks to the customer in spite of the customer.And then the third challenge is what I call the non-customers. It's very important to learn to listen to non-customers. So here I could give an example, one, for instance, kind of observed Fiskars's for instance, when they, the Finnish company that makes tableware and garden tools. So, for their cutting tools, for instance, they spend time with surgeons in operating rooms, you know. Or they look at first tree workers who cut trees in large scale. They're not like cutting small trees in the garden, but on a large scale and very often. And much more dramatic example is this company called EcoCem. It's in the cement business. They developed a new technology, a substitute for cement based on a technology called GGBS, which has much lower carbon footprint.And it is made out of a byproduct of the steel industry. So, it is very, very good for the environment. It has the same properties of traditional cement. Now, the only problem is that the dominant incumbents, were not looking at it very positively. So, when EcoCem tried to sell it to the customer, the customers we're hearing all this criticism from the dominant players, and they were not very keen on playing with it.It just happens at the cement industry is a very regulated industry. So, what EcoCem did instead of focusing on the customers, they focused their attention on their regulators. And they spent a lot of time engaging the regulators, bringing experts on the new technology to regulators. They managed to have the regulators actually accept and propose the new technology. And then the customers walked in. So, this is again, a very good example where the innovation didn't come by creating value to the customers, the construction companies. But to the regulators who are the people who can influence what the customer do. The Ewing Marion Kauffman FoundationSponsor Voice: The Ewing Marion Kauffman Foundation is a private, nonpartisan foundation based in Kansas City, Missouri, that seeks to build inclusive prosperity through a prepared workforce and entrepreneur-focused economic development. The Foundation uses its $3 billion in assets to change conditions, address root causes, and break down systemic barriers so that all people – regardless of race, gender, or geography – have the opportunity to achieve economic stability, mobility, and prosperity. For more  information, visit www.kauffman.org and connect with us at www.twitter.com/kauffmanfdn and www.facebook.com/kauffmanfdn.Brian Ardinger: And that's a good segue because I think a lot of folks think about innovation as this solo, mad scientist comes up with an idea and executes on it. But you talk a lot about in the book, this importance of collaboration. It is important engaging that idea with others and that. So can talk a little bit more about that process of collaboration. Ben Bensaou: I think this is very important, I would say that innovation is a team sport. And cross-functional teams are very important. And I always am surprised when I observed teams, to realize that it's not always the ones we think who are going to have that critical insights.So, it's very important to bring people with different mindsets. And then it's very important to close the gap. Close the distance between the would be innovators and the customers. Or there would be innovators in the company and the salespeople. For instance, I think these are two spaces and this is part of what I call the innovating engine.So maybe I can give an example of the first situation. This is about Kordsa. This is a Turkish company. They manufacturer fabric that is used to reinforce tires. On a regular basis, they send cross disciplinary team to their customer's plants. And these teams, they literally camp at the plants of the customers.They stay for a few days, and I've seen actually in the early days, they used to have a tent in the plant. And they just roam around, talk to people, observe what is happening in the plant. And these are cross-functional teams. You might have somebody from engineering, somebody from R and D, somebody from marketing, from legal, somebody from procurement.And at one plant, the team saw that the workers and the customer were having trouble to safely handle roles of reinforcing fabric that were loaded onto a truck. Now, again, this is an example of a silence of the customer. The customers knew the problem, they were facing the problem, but they didn't know the supplier could solve it.So, what happened is that this team at Kordsa, they just went back home and remedy the problems by developing a small kind of methodology, some process. They trained the customers into this new process, and they were able to help them reduce the resources from 30 minutes for three people to 12 minutes for one worker.And this was literally because they were able to go as a team and they close the gap between the team and the customer. So, it's very important to not only have multidisciplinary team, but also to bring the inside the firm first to bring the innovators together with the salespeople and then to bring the innovators together with the customer. Brian Ardinger: The last topic I want to talk about, and we talked briefly about it, but so everybody in the organization should be an innovator and should have the capabilities and aptitude to make things happen like that. But oftentimes middle managers and higher end managers either block that or change that. What are the roles of mid managers and upper management when it comes to innovation?Ben Bensaou: Let me talk to this as an example, and then I'll explain the roles. This is about Bayer, the global pharmacology and life science company based in Germany. So, this is a company that has a long history of scientific achievements through R and D and brilliant scientists. Yet in 2014, they decided to create from scratch to create an innovating engine, to leverage the capabilities of the hundred thousand employees in the company.So how did they do this? First, they made the whole board responsible for innovation. Then they selected 80 senior managers across all country groups and global functions. And these ambassadors, they made them as ambassadors. They were supporting these 80 senior managers became ambassadors, supporting the board. They were innovation ambassadors. And as ambassadors they spend most of their time with middle managers.Explaining, training, advocating, sponsoring innovation. And then they did something very important for these middle managers. They created a formidable support structure. Between 2016 and 2020, they trained and certified a thousand innovation coaches, which they activated locally across the whole company.And then for frontline people, they created WeSolve. This is a digital platform where any employee in Bayer can post information about a problem they're struggling with. And invite input and ideas from anyone in the company. So just to give you a sense. I visited the site once at any given time, they have 200 challenges posted on a platform. And then up to now, 40,000 employees at Bayer have participated in this platform. But to tell you the truth, Brian, what really impressed me the most in the statistic they showed me is that out of the best ideas that are proposed for all these challenges that are posted, two third of the best ideas effectively come from a department or unit different from where the person who posted the challenge works. This is to give you an example of what is a formal structure for an innovating engine. You can see that the senior leaders are the ones who have to give permission. They have the ones who have to give to permission to everybody to be able to innovate.They are the ones who create the governance structure, the coaches, and the local coordinators. Then the middle managers have a very important role. I was really surprised in my research to find out that middle managers are actually the key to innovation in corporate settings. Without middle managers, innovation gets lost.I've found it in any organization, senior leaders, they get it. They're facing a tough environment. They understand that without innovation, they can't survive. Frontline people, I mean the facing customers and non-customers on a daily basis. They understand that they have to innovate to solve the pain point and respond to the wishes and desires.But the middle managers are the ones who are caught in between because they don't have that direct pressure for innovation. And on top of it, they are the ones who are incentivized on execution. They're responsible for execution and they don't know if they don't get trained. They don't know how to help their people innovate.So, they need also this support structure to help them any time an individual or a team wants to innovate. They need to have these coaches. So, I would say you need to have senior leaders. You need to have the ones who create what I call the reframing. Allow for the organization to challenge the status quo challenge. Challenge the basic assumptions. The middle managers are the ones who participate in what I call the integration process. The process by which you connect the ideas and the people and the resources. And the process by which you winnow, channel, select, maybe prototype some of the best ideas before they get moved to the execution engine.So, this is a very important role for the middle managers. And they are the ones who support the frontline. And the frontline are the ones who have a huge contribution to make to what I call the creation process. The process by which the organization generates new ideas. New ideas are the raw material of innovation.And I explain how they do this by listening to the voice of the customer, the silence of the customer, and try to learn from non-customers. So, as I say, in this innovating engine, everybody has an important role to play. Senior leaders, middle managers and frontline innovators. For More InformationBrian Ardinger: And I encourage anybody who's listening to this podcast, who's in an innovation to pick up a copy of Built to Innovate. It's got a ton of great case studies, as you said. And it really helps set the framework for how you can start creating more of a culture of innovation within your company. If people want to find out more about yourself or the book, what's the best way to do that? Ben Bensaou: LinkedIn. I have a profile on LinkedIn. I have also my website on the INSEAD and then for the book, they can go to their local Amazon to find the book and to order it. Or they can go to the website for the book, which is BTIthebook.com. BTI for Built to Innovate thebook.com.Brian Ardinger: Well, Dr. Bensaou, thank you very much for being on Inside Outside Innovation. Really enjoyed the conversation and look forward to continuing it as the world changes in the future. Ben Bensaou: Thank you, Brian. It's a lot of fun.Brian Ardinger: That's it for another episode of Inside Outside Innovation. If you want to learn more about our team, our content, our services, check out InsideOutside.io or follow us on Twitter @theIOpodcast or @Ardinger. Until next time, go out and innovate.FREE INNOVATION NEWSLETTER & TOOLSGet the latest episodes of the Inside Outside Innovation podcast, in addition to thought leadership in the form of blogs, innovation resources, videos, and invitations to exclusive events. SUBSCRIBE HEREYou can also search every Inside Outside Innovation Podcast by Topic and Company.  For more innovations resources, check out IO's Innovation Article Database, Innovation Tools Database, Innovation Book Database, and Innovation Video Database.  As an Amazon Affiliate, we may earn a small commission from purchases.  

The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs: Big Pharma and the Hidden History of Addiction in America (U Chicago Press, 2020), David Herzberg explores these crises and the drugs that fueled them, from Bayer's Heroin to Purdue's OxyContin and all the drugs in between: barbiturate "goof balls," amphetamine "thrill pills," the "love drug" Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls "white markets," where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its "drug wars"--until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America's divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself--ideas that have been failing us catastrophically for over a century. David Herzberg is an associate professor of history at the University of Buffalo is also the author of Happy Pills in America from Milltown to Prozac. David is also the co-editor of the journal Social History of Alcohol and Drugs.  Jay Shifman is a vulnerable storyteller, a stigma-destroying speaker, and the founder of Choose Your Struggle podcast. A guy in long-term recovery, Jay is dedicated to ending stigma and promoting fact-based education around Mental Health, Substance Misuse & Recovery, and Drug Use & Policy. You can learn more about Jay at his links here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs: Big Pharma and the Hidden History of Addiction in America (U Chicago Press, 2020), David Herzberg explores these crises and the drugs that fueled them, from Bayer's Heroin to Purdue's OxyContin and all the drugs in between: barbiturate "goof balls," amphetamine "thrill pills," the "love drug" Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls "white markets," where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its "drug wars"--until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America's divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself--ideas that have been failing us catastrophically for over a century. David Herzberg is an associate professor of history at the University of Buffalo is also the author of Happy Pills in America from Milltown to Prozac. David is also the co-editor of the journal Social History of Alcohol and Drugs.  Jay Shifman is a vulnerable storyteller, a stigma-destroying speaker, and the founder of Choose Your Struggle podcast. A guy in long-term recovery, Jay is dedicated to ending stigma and promoting fact-based education around Mental Health, Substance Misuse & Recovery, and Drug Use & Policy. You can learn more about Jay at his links here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs: Big Pharma and the Hidden History of Addiction in America (U Chicago Press, 2020), David Herzberg explores these crises and the drugs that fueled them, from Bayer's Heroin to Purdue's OxyContin and all the drugs in between: barbiturate "goof balls," amphetamine "thrill pills," the "love drug" Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls "white markets," where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its "drug wars"--until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America's divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself--ideas that have been failing us catastrophically for over a century. David Herzberg is an associate professor of history at the University of Buffalo is also the author of Happy Pills in America from Milltown to Prozac. David is also the co-editor of the journal Social History of Alcohol and Drugs.  Jay Shifman is a vulnerable storyteller, a stigma-destroying speaker, and the founder of Choose Your Struggle podcast. A guy in long-term recovery, Jay is dedicated to ending stigma and promoting fact-based education around Mental Health, Substance Misuse & Recovery, and Drug Use & Policy. You can learn more about Jay at his links here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs: Big Pharma and the Hidden History of Addiction in America (U Chicago Press, 2020), David Herzberg explores these crises and the drugs that fueled them, from Bayer's Heroin to Purdue's OxyContin and all the drugs in between: barbiturate "goof balls," amphetamine "thrill pills," the "love drug" Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls "white markets," where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its "drug wars"--until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America's divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself--ideas that have been failing us catastrophically for over a century. David Herzberg is an associate professor of history at the University of Buffalo is also the author of Happy Pills in America from Milltown to Prozac. David is also the co-editor of the journal Social History of Alcohol and Drugs.  Jay Shifman is a vulnerable storyteller, a stigma-destroying speaker, and the founder of Choose Your Struggle podcast. A guy in long-term recovery, Jay is dedicated to ending stigma and promoting fact-based education around Mental Health, Substance Misuse & Recovery, and Drug Use & Policy. You can learn more about Jay at his links here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies

Episode 219: A new producer! In this episode, Dan is joined by Kansas City-based comedian and producer, Josh Shirley (The Art of Bombing Podcast) and they talk about wild crowds, listening to sets, and Josh joining the Art of Bombing team. Josh shares a bombing story at an event in which the crowd wanted to be part of the show, well kinda. Dan and Josh also discuss the future of the show as Dan welcomes Josh to the Art of Bombing Team. Plus more! Please rate and review.Josh ShirleyJosh is a stand-up comic based out of Kansas City, MO. He performs clean comedy at clubs and speaks at corporate events. Josh has appeared in national commercials for Sprint, Bayer, and UPS. He's opened for Elliott Threatt, James Johann, and Dan Bublitz Jr. Website: Josh Shirley Twitter: @LaughingatJosh  Instagram: @joshshirleycomedy Art of Bombing:  Dead & Mellow: https://deadandmellow.com/  "Nobody Had a Podcast Called The Art of Bombing" Theme by John Hult  Bumpers provided by Joe Nicola Music  Website: https://www.artofbombingpod.com/    Merch: https://teespring.com/stores/blitzed-entertainment Buy me a beer: https://www.buymeacoffee.com/dbubcomedy  Patreon: https://www.patreon.com/artofbombingpod  FB: https://www.facebook.com/artobpodcast/  Twitter: @artofbombingpod  Instagram: @artofbombingpod  YouTube: Art of Bombing Podcast  Dan Bublitz Jr: http://www.danbublitz.com/  ★ Support this podcast on Patreon ★

Sam and Emma host Bart Elmore, Associate Professor of History at The Ohio State University, to discuss his recent book Seed Money: Monsanto's Past and Our Food Future, on the role Monsanto has played in shaping our agricultural production around the sale of chemicals, and chemicals to counteract those chemicals, all while promoting it as a food production revolution. They begin with the onset of both Professor Elmore's study of Monsanto, and the seeds of the company itself, with John Queeny's company serving as a chemical business alternative to the German pharmaceutical company Bayer, despite only really producing sweeteners and caffeine for the Coca Cola company, before his son Edgar takes the reins in the late 1920s and begins to broaden the company's output to chemicals for soaps and plastics, with his eyes already set on agriculture and food production. Monsanto's production throughout the next few decades centered on creating toxic compounds for dual purposes: the destruction of human life, and the destruction of unneeded plant, insect, and parasitic life. This resulted in the birth of a variety of new chemicals, starting with DDT and working up to 2,4,5-T, the central element of Agent Orange, in the 40s, as Professor Elmore walks through the effects of the production on the factory workers, who fell deathly ill, facing conditions including rampant chloracne, eventually taking a case against Monsanto in the ‘80s, which would lead to the company leveraging their workers' own housing against them. Next, he brings Emma and Sam up to the neoliberal era, as Monsanto tried to work away from warfare and back towards agriculture, bringing about their Roundup product in the ‘70s, as it took off in the ‘80s after early EPA approval, a bolstering of the company by George H.W. Bush's competitiveness council, and a cornering of the market when the company discovered an agrobacterium in the dump outside of their factories that was resistant to the Roundup herbicide. They finally jump into the actual shifting of agricultural industry that Monsanto caused, looking at their pushback of both research that countered the belief that their chemicals would not create resistant bacteria, and of farmers that “benefitted” from their product without purchasing it. Lastly, they cover the continuation of this corporate culture of environmental and agricultural destruction for profit as Professor Elmore dives into the recent production of dicamba and the lawsuits that are currently ongoing, even as Bayer, ironically, has undergone a takeover of the chemical company, all while research surfaces proving that Monsanto's inventions had no significant impact on food yields. Sam and Emma also touch on the upcoming Starbuck unionization attempt and look back at this day in history in 1898, with the Wilmington, NC insurrection by white supremacists. And in the Fun Half: The MR team take a call from the one and only Kowalski from Nebraska in the wake of the Monsanto interview, Marlon from LA calls in for some clarification on the two bills working through Congress, and Nancy Pelosi fittingly officiates the wedding of an Heiress to an Oil fortune alongside her appearance at COP 26. Terry Crews puts Amazon storage workers to shame as he proves you just have to be famous and insanely muscular to survive there, Shashank from NY discusses the roots of the term pariah, and Charlie Kirk calls today's kids gay America haters, and, frankly, we're honored, plus, your calls and IMs! Purchase tickets for the live show in Boston on January 16th HERE! Become a member at JoinTheMajorityReport.com Subscribe to the AMQuickie newsletter here. Join the Majority Report Discord! http://majoritydiscord.com/ Get all your MR merch at our store https://shop.majorityreportradio.com/ (Merch issues and concerns can be addressed here: majorityreportstore@mirrorimage.com) You can now watch the livestream on Twitch Check out today's sponsors: MySolarNerd.com: There are a lot of homeowners that aren't aware of the solar options currently available. It is now possible to retrofit a home with solar panels for no money down. Most homeowners that switch over to solar see significant savings starting in their first year. This is possible thanks to the Solar Investor Tax Credit (going away soon). My Solar Nerd's mission is SIMPLE: Help you find the best solar program for your home and make the transition as EASY and SMOOTH as possible. Go to mysolarnerd.com and fill out the inquiry form now. Make sure you select Majority Report Listener for how you heard about My Solar Nerd to receive a $200 gift card upon installation! Support the St. Vincent Nurses today as they continue to strike for a fair contract! https://action.massnurses.org/we-stand-with-st-vincents-nurses/ Subscribe to Discourse Blog, a newsletter and website for progressive essays and related fun partly run by AM Quickie writer Jack Crosbie. https://discourseblog.com/ Subscribe to AM Quickie writer Corey Pein's podcast News from Nowhere, at https://www.patreon.com/newsfromnowhere Check out Matt's show, Left Reckoning, on Youtube, and subscribe on Patreon! Subscribe to Matt's other show Literary Hangover on Patreon! Check out The Letterhack's upcoming Kickstarter project for his new graphic novel! https://www.kickstarter.com/projects/milagrocomic/milagro-heroe-de-las-calles Check out Matt Binder's YouTube channel! Subscribe to Brandon's show The Discourse on Patreon! Check out The Nomiki Show live at 3 pm ET on YouTube at patreon.com/thenomikishow Check out Jamie's podcast, The Antifada, at patreon.com/theantifada, on iTunes, or at twitch.tv/theantifada (streaming every Monday, Wednesday, Thursday and Friday at 7pm ET!) Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattBinder @MattLech @BF1nn @BradKAlsop Donate to Lance aka Gimpy G on Twitch's GoFundMe here!